Biotherapeutics News
-
Bened Biomedical Completes $10M Series A, Set for Expansion into US Healthcare Market
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
-
Bened Biomedical Affiliates US Distributor, Now Bened Life
Bened Biomedical Co, LTD., the global leader in psychobiotics with clinical studies, has acquired its US distributor Oryx Biomedical, Inc., who is pioneering the translation of microbiome research into impactful biotherapeutics and is one of the earliest stage companies bringing the gut-brain axis category of probiotics to the market. Based in Taiwan and founded by Prof. Ying-Chieh Tsai, PhD, ...
-
New partnership to advance glycoproteomics and biotherapeutics tools and research
Protein Metrics Inc., a leading provider of biopharmaceutical and proteomics analysis software, announced today a new partnership to advance glycoproteomics and biotherapeutics tools and research Macquarie University’s Analytical Glycoimmunology Group and Protein Metrics Inc. today have launched a strategic partnership scheme to further advance glycoproteomics and biotherapeutics ...
-
Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. The associated patents broadly cover foundational elements for the rapid, targeted delivery of drugs, including ...
By Suono Bio
-
Analyzing Protein Structures with Pronalyse’s Hydrogen Deuterium Exchange Mass Spectrometry
Pronalyse is a subdivision of Creative Proteomics, an integrated CRO company with rich experience in providing drug development services. Based on years of experience supporting protein characterization research, Creative Proteomics Pronalyse introduces hydrogen-deuterium exchange mass spectrometry to help scientists accelerate the study of advanced protein structures. HDX-MS ...
-
7 December 2022 - FDA/CDC highlight need for infection preventions
Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and US Centers for ...
-
CD Formulation Stresses the Importance of Increased Bioavailability Excipients in Drug Formulation
Specializing in drug formulation, the highly specialized CRO service provider CD Formulation has accumulated abundant experience in the custom synthesis of increased bioavailability excipients. To meet the requirements of different drug research projects, excipients can be tailor-made in varied specifications and volumes. Recently, adding increased bioavailability excipients in drug formulations ...
-
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
New York, New York, November 10, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and ...
-
CD BioGlyco Released Characterization Service of Glycosylation in Protein Drugs
CD BioGlyco, a leader in glycosylation characterization, recently developed a comprehensive glycoproteomics platform to provide its customers worldwide with the characterization of glycosylation in protein drugs. Glycoproteins, such as glycosyltransferases, glycosidases, erythropoietin, and cytokines, make up the majority of biotherapeutic products. Although the drugs themselves are ...
By CD BioGlyco.
-
Pronalyse Supports Drug Discovery with the Launch of Biosimilar Analysis Solutions
Pronalyse is a protein characterization division of Creative Proteomics, an integrated CRO with rich experience in providing drug development services. Based on years of experience supporting the development of biosimilars, Creative Proteomics can provide comprehensive Biosimilar Analysis Solutions. A biosimilar is a biological product that is similar to an approved biological originator, ...
-
Eagle Genomics Announces USD 20M First Close; Scale-up Funding to Accelerate the Application of Microbiome Science for Global ‘One Health’ Innovation
Funds to support scale-up, including continued development of AI-augmented knowledge discovery platform, the e[datascientist]™, and continued international expansion Platform business focused on bridging the current ‘translation gap’, addressing critical bottlenecks in the industrial application of microbiome science – from soil, to plant, to farm, to fork, to human, ...
-
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in Washington DC. As part of the presentation, LISCure ...
-
Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update
Company announces completion of Phase 1 dose escalation ahead of schedule for IO-108, a first-in-class antibody targeting LILRB2 (ILT4) Signals of clinical activity observed in multiple tumor types for IO-108 as a single agent and in combination with an anti-PD-1 Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel ...
-
Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
New York, New York, October 18, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today the completion of a series of related recapitalization transactions designed to enhance shareholder value. These transactions include the elimination of ...
-
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-108 in Patients with Advanced Solid Tumors in China
IO-108 is the first LILRB2-targeting antibody administered to Chinese patients Implementation of IO-108 program in China initiates Immune-Onc’s global clinical development plan; Phase 1 trial has completed dose escalation in the U.S. in solid tumor patients Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel ...
-
The HealthTech For Care Innovation Award will be presented for the first time at the HealthTech Innovation Days on October 13 and 14, 2022 in Paris.
25 European companies from the Biotech, Medtech, Innovative Services & Digital Health sectors, committed to patients, selected by the European clusters, will present their innovation to a jury composed of HTFC’s sponsors and the HTID health innovation ecosystem. The HealthTech Innovation Days (HTID®) event, organized by the HealthTech For Care (HTFC) endowment fund, is launching ...
-
Meet us at PDA 2022
2022 PDA : the Scientific Program Planning Committee and the PDA have joined forces with the Lyophilization Conference to provide a comprehensive experience that includes all emerging trends in biomanufacturing. In this context, Indatech teams will be present at the 2022 PDA BioManufacturing Conference with great demonstrations of NIR Hyperspectral and UV VIS! The health emergency has ...
-
MOBILion Systems Appoints Jenn Buechel to its Board of Directors
MOBILion System Inc. (Chadds Ford, PA), a life science tools and instrumentation company commercializing a best-in-class technology to separate, identify, and analyze the most challenging molecules other instruments fail to detect, announced that it has appointed Jenn Buechel to serve on its Board of Directors, effective immediately. Ms. Buechel, currently the Chief Operating Officer of Delfi ...
-
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer. Waisman Biomanufacturing has entered an agreement with BriaCell to ...
-
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
Plan ensures shareholders are protected and treated equitably Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Jun. 10, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you